DSM Biologics offers state-of-the-art facilities and contract manufacturing expertise to our customers, and delivers the right quantity and quality of biopharmaceutical products within the agreed customer timelines. Our service portfolio includes manufacture of therapeutic recombinant proteins, monoclonal antibodies, fusion proteins, and antibody fragments.
Our Groningen plant is designed to address all of our customer needs. The plant comprises process development and cGMP facilities of ~20,000 ft2 (~1,860m2) each. The cGMP area contains suites with 50 L, 250 L, 500 L, and 1,000 L single-use and stainless steel bioreactors, as well as several DSP suites equipped with filtration devices (dead-end, cross-flow filtration) and all of the necessary types of chromatography operation (resins or membrane). Commercial production will begin in 2013 in a new Brisbane, Australia, facility. DSM Biologics provides a full range of analytical development capabilities as well as regulatory support to all customers.
DSM Biologics’ unique position in being able to utilize innovative and superior process technologies, like the proprietary XD® and Rhobust® technologies (Figure 1), makes the company a sought-after technology provider.